

11 September 2025

Our Ref: FOI 1353

Dear

**Freedom of Information Act 2000
Information in Relation to Treatment of Haematology**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 14 August 2025.

A response to the questions you have raised has been provided by the Surgery, Elective, Maternity and Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Olivia Robinson
Information Governance Officer

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

- **Acalabrutinib (Calquence)**
- **Ibrutinib (Imbruvica)**
- **Pirtobrutinib (Jaypirca)**
- **Venetoclax (Venclyxto)**
- **Zanubrutinib (Brukinsa)**
- **Rituximab**
- **Obinutuzumab (Gazyvaro)**

A1. Please see Table 1 below for the number of patients treated in total, regardless of diagnosis, with the listed medicines in the 3 months between 1 April 2025 and 30 June 2025.

Table 1

Name of Medicine	Number of Patients Treated
Acalabrutinib (Calquence)	7
Ibrutinib (Imbruvica)	7
Pirtobrutinib (Jaypirca)	Nil
Venetoclax (Venclyxto)	13
Zanubrutinib (Brukinsa)	3
Rituximab	59
Obinutuzumab (Gazyvaro)	24

Q2. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines in the 3 months between the start of October 2024 and end of December 2024, or the latest 3-month period available?

- **Acalabrutinib (Calquence)**
- **Ibrutinib (Imbruvica)**
- **Pirtobrutinib (Jaypirca)**
- **Venetoclax (Venclyxto)**
- **Zanubrutinib (Brukinsa)**
- **Obinutuzumab (Gazyvaro)**
- **Rituximab**

- **Bendamustine**
- **Chlorambucil**
- **Fludarabine**
- **Cyclophosphamide**

A2. Please see Table 2 for the number of patients with Chronic Lymphocytic Leukaemia or Small B-Cell Lymphoma treated with the listed medicines in the 3 months between 1 October 2024 and 31 December 2024

Table 2

Name of Medicine	Number of Patients Treated
Acalabrutinib (Calquence)	7
Ibrutinib (Imbruvica)	7
Pirtobrutinib (Jaypirca)	Nil
Venetoclax (Venclyxto)	8
Zanubrutinib (Brukinsa)	2
Obinutuzumab (Gazyvaro)	8
Rituximab	Nil
Bendamustine	Nil
Chlorambucil	Nil
Fludarabine	Nil
Cyclophosphamide	Nil

Q3. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

- **Ibrutinib + venetoclax**
- **Obinutuzumab + venetoclax**
- **Zanubrutinib monotherapy / maintenance**
- **Ibrutinib monotherapy / maintenance**
- **Venetoclax monotherapy**
- **Venetoclax + rituximab**

A3. Please see Table 3 for the number of patients with Chronic Lymphocytic Leukaemia or Small B-Cell Lymphoma treated with the listed medicines as monotherapy, or in combination, in the 3 months between 1 April 2025 and 30 June 2025.

Table 3

Name of Monotherapy or Combination	Number of Patients Treated
Ibrutinib + venetoclax	Nil
Obinutuzumab + venetoclax	4
Zanubrutinib monotherapy / maintenance	1
Ibrutinib monotherapy / maintenance	4
Venetoclax monotherapy	3
Venetoclax + rituximab	2

Q4. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

- **Acalabrutinib**
- **Ibrutinib**
- **Zanubrutinib**

A4. Please see Table 4 for the number of patients with Mantle Cell Lymphoma treated with the listed medicines in the 3 months between 1st April 2025 and 30 June 2025

Table 4

Name of Monotherapy or Combination	Number of Patients Treated
Acalabrutinib	Nil
Ibrutinib	2
Zanubrutinib	Nil

Q5. How many patients with Acute Myeloid Leukaemia – ICD10 code = C920 - were treated with the following medicines in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?

- **Azacitidine**
- **Cytarabine**
- **Venetoclax (Venclyxto)**

- A5. Please see Table 5 for the number of patients with Acute Myeloid Leukaemia treated with the listed medicines in the 3 months between the 1 April 2025 and 30 June 2025.

Table 5

Name of Medicine	Number of Patients Treated
Azacitidine	9
Cytarabine	1
Venetoclax (Venclyxto)	5

- Q6. How many patients with Acute Myeloid Leukaemia were treated with the following medicines in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

- **Venetoclax + Azacitidine (with or without posaconazole)**
- **Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)**

- A6. Please see Table 6 for the number of patients with Acute Myeloid Leukaemia that were treated with the listed medicines in combination in the 3 months between 1 April 2025 and 30 June 2025..

Table 6

Name of Combination	Number of Patients Treated
Venetoclax + Azacitidine (with or without posaconazole)	5
Venetoclax + Cytarabine (inc. V + LDAC, V + ARAC, V+ ARA-C)	1

- Q7. How many patients with Multiple Myeloma were treated with the following medicines in combination, in the 3 months between the start of April 2025 and end of June 2025, or latest 3-month period available?**

- **Daratumumab + Bortezomib + Dexamethasone [DVd]**
- **Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd]**
- **Daratumumab + Lenalidomide + Dexamethasone [DRD]**
- **Lenalidomide + Dexamethasone [Rd]**
- **Lenalidomide (monotherapy)**
- **Carfilzomib + Lenalidomide + Dexamethasone [KRd]**
- **Elotuzumab + Lenalidomide + Dexamethasone [ERd]**

- ***Ixazomib + Lenalidomide + Dexamethasone [IRd]***
- ***Belantamab Mafodotin (monotherapy)***
- ***Belantamab Mafodotin + Bortezomib + Dexamethasone [BVd]***
- ***Any other combination containing Lenalidomide (please specify):***

A7. Please see Table 7 for the number of patients with Multiple Myeloma treated with the listed medicines in combination in the 3 months between 1 April 2025 and 30 June 2025.

Table 7

Name of Medicine	Number of Patients Treated
Daratumumab + Bortezomib + Dexamethasone [DVd]	3
Daratumumab + Bortezomib + Thalidomide + Dexamethasone [DVTd]	2
Daratumumab + Lenalidomide + Dexamethasone [DRD]	25
Lenalidomide + Dexamethasone [Rd]	18
Lenalidomide (monotherapy)	30
Carfilzomib + Lenalidomide + Dexamethasone [KRd]	2
Elotuzumab + Lenalidomide + Dexamethasone [ERd]	Nil
Ixazomib + Lenalidomide + Dexamethasone [IRd]	1
Belantamab Mafodotin (monotherapy)	Nil
Belantamab Mafodotin + Bortezomib + Dexamethasone [BVd]	2
Any other combination containing Lenalidomide (please specify):	Nil